We highly recommend enabling Javascript while using the BlackBoxRX site.

Coagulation Factor Xa (andexanet alfa)

Thromboembolic Risks, Ischemic Risks, Cardiac Arrest, and Sudden Deaths

Treatment with ANDEXXA has been associated with serious and life-threatening adverse events, including: 

  • Arterial and venous thromboembolic events
  • Ischemic events, including myocardial infarction and ischemic stroke
  • Cardiac arrest
  • Sudden deaths

Monitor for thromboembolic events and initiate anticoagulation when medically appropriate. Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed.

Patient Counseling Information

Package Inserts

Coagulation Factor Xa (Andexanet Alfa)

Updated August 2019